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Abstract: -Conotoxins are disulfide-rich peptides that target nicotinic acetylcholine receptors. Recently we identified several -conotoxins 
that also modulate voltage-gated calcium channels by acting as G protein-coupled GABAB receptor (GABABR) agonists. These -conotoxins 
are promising drug leads for the treatment of chronic pain. To elucidate the diversity of -conotoxins that act through this mechanism we 
synthesized and characterized a set of peptides with homology to -conotoxins known to inhibit high voltage-activated calcium channels via 
GABABR activation. Remarkably, all disulfide isomers of the active -conotoxins Pu1.2 and Pn1.2, and the previously studied Vc1.1 showed 
similar levels of biological activity. Structure determination by NMR spectroscopy helped us identify a simplified biologically active eight 
residue peptide motif containing a single disulfide bond that is an excellent lead molecule for developing a new generation of analgesic 
peptide drugs. 
Marine snails of the Conus genus produce venom, composed of a range of bioactive disulfide-rich peptides known as 
conotoxins, that is used for both defense and for prey capture.[1] Members of the α-conotoxin subfamily (Figure 1) are defined as 
neuronal or muscle nicotinic acetylcholine receptors (nAChRs) antagonists.[2]  
 
 
 
Figure 1. Selected -conotoxins and their conserved structural framework. (A) Sequences of -conotoxins that inhibit high voltage-activated (HVA) calcium 
channel currents (ICa) via the GABAB receptor (in red) and homologous sequences that have been investigated in this study (in black). The boxes indicate 
groupings of homologous sequences; cysteines are highlighted in yellow and numbered with Roman numerals, and the native CysI – CysIII, CysII – CysIV 
connectivity is indicated by solid black lines (top). An asterix indicates an amidated C-terminus. The two loops of the -conotoxins are indicated at the bottom. (B) 
A schematic illustration of the three possible disulfide isomers for an -conotoxin: the globular isomer (CysI – CysIII, CysII – CysIV, top), the ribbon isomer (CysI – 
CysIV, CysII – CysIII, middle), and bead isomer (CysI – CysII, CysIII – CysIV, bottom). (C) The three-dimensional structure of Vc1.1 highlighting the helical nature 
of the -conotoxins, the cysteine framework (Roman numerals), the two disulfide bonds (yellow ball and sticks) and the two sequence loops. 
α-Conotoxins Vc1.1[3] and RgIA[4] have been of recent interest as drug leads, because they have analgesic properties in rat 
models of neuropathic pain.[5] Recently, a backbone cyclisation strategy was used to develop an orally active analogue of Vc1.1.[6] 
Vc1.1 and RgIA are α9α10 nAChR subtype antagonists, and potently inhibit N-type (Cav2.2) and R-type (Cav2.3) calcium channels 
via GABAB receptor (GABABR) activation.
[7] GABABR agonists have been shown to relieve neuropathic and chronic pain.
[8] 
Subsequently, three other conotoxins, PeIA[9], AuIB[5d] and Vc1.2[10], have also been shown to inhibit HVA calcium channels via a 
GABABR-dependent mechanism (Fig 1A). 
 
 α-Conotoxins contain four cysteine residues, so can potentially form three disulfide isomers during oxidative folding (Fig 1B). 
These include the globular isomer (CysI-CysIII and CysII-CysIV), the ribbon isomer (CysI-CysIV and CysII-CysIII) and the beads 
isomer (CysI-CysII and CysIII-CysIV). The natively preferred disulfide connectivity for wild-type α-conotoxins is typically the globular 
isomer although the ribbon isomer of the α-conotoxin ImI was detected in the venom of Conus imperialis.[11] The three dimensional 
structure of the α-conotoxin globular isomer consists of a helical turn that is cross-braced by two disulfide bonds (Fig 1C). This 
structure orientates the side chains of the peptide to facilitate the binding of the conotoxin between two subunits of the pentameric 
nAChR.[12] Interestingly, the ribbon isomer of several α-conotoxins has been shown to inhibit nAChRs.[13] Therefore, exploring the 
effect of disulfide connectivity could provide valuable information on structure/activity relationships, and lead to the discovery of new 
bioactive molecules. 
 
Here we focus on expanding our knowledge of the sequence and structural diversity of α-conotoxins that target the GABABR. 
Based on sequence homology to Vc1.1, RgIA, AuIB or PeIA, we chose six α-conotoxins from the ConoServer database (Figure 
1A).[14] The globular isomers of each peptide were synthesized by Fmoc solid-phase peptide synthesis with regioselective disulfide 
bond formation using S-acetamidomethyl (Acm) protection on CysI and CysIII. Peptides were obtained in high purity and acceptable 
yield (6 to 18%) after HPLC purification (Figure S1).  
 
The purified globular isomers for all six peptides gave well dispersed signals in their 1H NMR spectra, implying they adopt 
ordered structures in solution. They were further analyzed by two-dimensional NMR  and secondary Hα shift analysis showed the 
peptides adopted a fold consistent with other α-conotoxins (Figure S3A-C), including a series of negative secondary shift values in 
the central portion of the peptide that is indicative of helical secondary structure.[15] 
 
The conotoxins were tested for their ability to inhibit HVA calcium channel currents (ICa) in rat DRG neurons. α-Conotoxins 
Pn1.2, Pu1.2, Kn1.2 and Tx1.2 inhibited ICa by ~22, 27, 13 and 8%, respectively. In comparison, Ai1.2 and Bu1.1 did not modulate ICa 
(Figures 2A and S9). These results expand the known number and sequence diversity of α-conotoxins that inhibit HVA calcium 
channel currents. It was previously shown that non-native disulfide isomers of α-conotoxins are biologically active.[13] Therefore, to 
explore the structural elements required for calcium channel inhibition via GABABRs, we synthesized the three possible disulfide 
isomers of Pn1.2, plus Pu1.2 and Vc1.1.  
 
As described for the globular isomer syntheses, we used Fmoc SPPS and Acm protection on specific pairs of cysteines to 
produce the ribbon and beads isomers of Pn1.2, Pu1.2 and Vc1.1. NMR analyses revealed that all isomers adopted a single 
conformation in solution, except for the Pn1.2 globular isomer and all three beads’ isomers. These peptides showed other minor 
conformations, presumably due to proline cis/trans isomerization. However this was only confirmed for the Pn1.2 globular isomer 
(Table S1). Chemical shift assignments and secondary shift analyses for all disulfide isomers are given in Tables S2-4 and Figure S4. 
 
 Surprisingly, all isomers inhibited ICa in rat DRG neurons (Figure 2B) and there was no significant difference in inhibitory activity 
between individual isomers of each peptide. All α-conotoxin isomers were stable during the assay and no disulfide shuffling between 
isomers was observed (Figure S8). We have shown that both reduced and alkylated Vc1.1 have no effect on HVA calcium channel 
currents.[7] Therefore, the observed activity can be attributed to specific isomers and suggests there might be a common bioactive 
motif between each isomer. 
 
Figure 2. (A) Averaged relative peak ICa amplitudes (I/Icontrol) ± SEM in the presence of various -conotoxins (1 M). The relative peak ICa amplitudes (I/Icontrol) in 
the presence of -conotoxin Pn1.2, Tx1.2, Kn1.2 or Pu1.2 were 0.78  0.034, 0.73  0.019, 0.87  0.040 and 0.92  0.023 (mean  SEM), respectively, whereas 
Bu1.1 and Ai1.2 did not modulate ICa. The number of experiments is in parentheses (B) The beads (b), globular (g) and ribbon (r) disulfide isomers of -conotoxins 
Pn1.2, Pu1.2 and Vc1.1 inhibit ICa in rat DRG neurons. Mean relative peak ICa amplitudes (I/Icontrol) ± SEM in the presence of each -conotoxin (1 M) are shown. 
The number of experiments is in parentheses. The specific GABABR agonist baclofen (bac, 50 M) was used as a positive control. The dotted line indicates 
maximum current recorded in the absence of -conotoxin (control). 
To further understand the common structural elements in the three isomers, we determined the three dimensional structures of 
the globular, ribbon and beads isomers of Pu1.2. Structures were calculated in CYANA 3.0[16] and refined in CNS[17] using NOE 
derived distance restraints, TALOS-N[18] derived dihedral angle restraints, and hydrogen bond restraints from D2O exchange 
experiments. The structural statistics for the ensemble of the 20 lowest energy structures for each isomer are shown in Table S5. 
Figure 3 shows the lowest energy structure from each structural ensemble. 
 
Both the globular and ribbon isomers had well-defined structures, with the globular isomer possessing the characteristic helical 
nature of an α-conotoxin. The beads isomer had two defined loop regions (Gly2-Pro8) and (Cys9-Cys16), separated by a flexible 
hinge (Figure S6). The surface features of all three isomers consist of a series of alternating polar and hydrophobic patches, with the 
major hydrophobic region formed by Pro7, Pro8, Ile10 and Ala11 (Figure S7). There were no obvious structural similarities between 
the three isomers, but there was some indication of common loop motifs. For example, the backbone RMSD from residues Cys3-
Pro8 for all 60 structures was only 0.954 Å. 
 
Figure 3. The three dimensional structures of the (A) globular (green); (B) ribbon (red); and (C) beads (blue) disulfide isomers of -conotoxin Pu1.2. The structure 
shown for each isomer is the lowest energy conformer from an ensemble of the 20 lowest energy structures calculated using CYANA[16] and refined in CNS[17]. 
Structures are shown in ribbon format with disulfide bonds in ball and stick, and the cysteines and N and C termini labelled.  
To see if any loop regions in the Pu1.2 isomers form the core requirement for calcium channel inhibition, we made a set of 
truncated and disulfide deficient Pu1.2 mutants (Figure 4A). These consisted of full-length ([Ser3, Ser9] Pu1.2(1-16)), loop 1 alone 
([Ser4]Pu1.2(1-9)) and loop 2 (Pu1.2(9-16)) alone, each with a single disulfide bond restraint. The peptides were synthesized by 
Fmoc-based SPPS, and the disulfide bond formed by incubating the peptide in 0.1M NH4HCO3 with 2.2’-bispyridyl disulfide, purified 
by HPLC and characterized by NMR spectroscopy (Figure S5).  
 
The truncated loop 1 peptide, [Ser4]Pu1.2(1-9), was sufficient to inhibit HVA calcium currents in rat DRG neurons and this effect 
could be blocked by a 4 min pre-incubation with the selective GABABR antagonist CGP55845 (Figure 4B). The analogues [Ser
3, 
Ser9]Pu1.2(1-16) and Pu1.2(9-16) were inactive. As the loop 1 region of Pu1.2 was sufficient for biological activity, we decided to 
extrapolate this finding to Vc1.1. Interestingly, both Vc1.1 and RgIA, which were the first α-conotoxins shown to inhibit HVA ICa via the 
GABABR, have identical loop 1 sequences but vary significantly in length and composition of loop 2. Subsequent synthesis and 
testing of the loop 1 analogue of Vc1.1, [Ser3]Vc1.1(1-8), revealed it inhibited HVA calcium currents in mouse DRG neurons with a 
potency comparable with full-length Vc1.1 (Figure 4C). These truncated, single disulfide conotoxin analogues could be promising 
lead molecules for the development of new analgesics.  
 
Vc1.1, RgIA and their backbone cyclic analogues have all been proposed as potential leads for drugs to treat neuropathic and 
chronic pain. Compared with these full-length peptides, the truncated versions have the advantage of structural simplicity, making 
their synthesis faster, less expensive and more efficient. Of note is that loop 1 of Vc1.1 and RgIA is also identical in sequence to that 
of ImI, which did not inhibit HVA calcium currents in rat DRG neurons.[7b] This suggests residues in loop 2 can also influence 
interactions with GABABR, which is consistent with our previous study showing that post-translational modification of Glu
14 in Vc1.1 to 
-carboxyglutamic acid resulted in a loss of HVA calcium channel inhibitory activity.[7b] Furthermore, post-translational modification of 
Pro6 of Vc1.1 to hydroxyproline also caused a loss of HVA calcium current inhibition suggesting that this residue, which is present in 
both [Ser3]Vc1.1(1-8) and [Ser4]Pu1.2(1-9), might be a key interaction site with the GABABR. 
 
Figure 4. Truncated analogues of Pu1.2 and Vc1.1 inhibit HVA calcium currents in rat and mouse DRG neurons. (A) The sequences of truncated and disulfide-
deficient analogues of Pu1.2 and Vc1.1. Disulfide bonds are indicated by a solid line. The asterisk indicates an amidated C-terminus and the positions of the 
cysteines substituted with serine are underlined. (B) ICa inhibition in the presence of full-length disulfide-deficient or truncated Pu1.2 analogues. Bar graphs 
represent averaged relative peak ICa amplitude (I/Icontrol)  SEM values. The number of experiments is shown in parentheses. The asterisk indicates the difference 
between CGP55845 + [Ser4]Pu1.2(1-9) and [Ser4]Pu1.2(1-9) groups. Statistical significance was assessed using ANOVA (* P < 0.05). (C) Average I/Icontrol data ( 
SEM) of peak ICa inhibition in mouse DRG neurons. ICa was inhibited by 23.5 ± 4% (1 M [Ser
4]Pu1.2(1-9)), 30.2 ± 3.9%, 31.6 ± 4% and 20.6 ± 3.3% (1-3 M, 30 
nM and 100 pM [Ser3]Vc1.1(1-8), respectively, or 41.5 ± 2.7% (50 M baclofen). The number of experiments is in parentheses. The effect of Vc1.1(1-
8)[Ser3]Vc1.1(1-8) developed slowly, reached maximum inhibition within 10 min, and was irreversible. In comparison, the effect of [Ser4]Pu1.2(1-9) was transient, 
with ICa showing partial recovery in the presence of this analogue (see also Figure S9). Similarly, ~20%, ICa inhibition values were obtained in rat DRG neurons in 
the presence of 1 M Vc1.1(1-8) (n = 3) (not shown). (D) Representative tracing of the visceromotor response (VMR) to colorectal distension in mice. The upper 
panel shows the distension sequence (20 s duration, 4 min interval). The corresponding EMG recordings after intra-colonic administration with either vehicle or 
1000 nM [Ser3]Vc1.1(1-8) are illustrated in the middle and lower panel respectively. VMR to colorectal distension were notably reduced by [Ser3]Vc1.1(1-8). (E) In 
healthy control mice intracolonic administration of [Ser3]Vc1.1(1-8) (filled circles) significantly reduced VMR to 60 and 80 mmHg of distension, when compared to 
intracolonic vehicle treatment (open circles). Data expressed as area under the curve of the corresponding EMG signal for n=4mice/group. (*P < 0.05, ***P < 
0.001, n=4 mice, two-way ANOVA, Bonferroni posthoc). 
We tested all Pu1.2 analogues and [Ser3]Vc1.1(1-8) for their ability to inhibit human α9α10 and α7 nAChRs expressed in 
Xenopus oocytes. None inhibited hα9α10 nAChRs, but 1 M [Ser3]Vc1.1(1-8) fully inhibited hα7 nAChRs (Figure S12). This is 
consistent with a study showing a disulfide-deficient analogue of ImI, without CysII-CysIV, retained its affinity for rat α7 nAChRs 
comparable with the native peptide.[19] The key residues for inhibition of currents through α7 nAChRs by ImI is the Asp-Arg-Pro motif 
in loop 1, which is present in [Ser3]Vc1.1(1-8).[19] This key Asp-Arg-Pro motif is not present in [Ser4]Pu1.2(1-9), which likely explains 
why this peptide does not inhibit α7 nAChRs. 
 
We determined if [Ser4]Pu1.2(1-9) or [Ser3]Vc1.1(1-8) could modify colonic nociceptor function.[20] To do this, we performed ex 
vivo afferent recordings from mouse splanchnic high-threshold nociceptors, which respond to focal compression and noxious 
stretch/distension.[21]
 
We assessed nociceptor mechanosensitivity before and after increasing doses of each peptide. Both 
[Ser4]Pu1.2(1-9) and [Ser3]Vc1.1(1-8) dose-dependently inhibited colonic nociceptor mechanosensitivity, with greatest inhibition 
observed at a concentration of 1000 nM (Figure S14). We then assessed the effect of [Ser3]Vc1.1(1-8) in a mouse model of visceral 
pain. Noxious distension of the colorectum triggers the visceromotor response (VMR), a nociceptive brainstem reflex consisting of 
contraction of the abdominal muscles.[22] Abdominal electromyography (EMG), was used to assess visceral sensitivity in vivo in fully 
awake animals.[23] In this model, intracolonic treatment with [Ser3]Vc1.1(1-8) significantly reduced VMR in response to colorectal 
distension compared to vehicle treated mice (Figure 4C-D). 
 
In conclusion, we have described four new α-conotoxins that inhibit HVA calcium channels via GABAB receptor activation in rat 
DRG neurons.  We have also identified a core peptide motif that inhibits HVA calcium channels and blocks nociceptor 
mechanosensitivity. Synthesis of peptides with multiple disulfide bonds can be technically challenging, and shuffling of disulfide 
bonds is problematic for drug development. Therefore, this simplified core peptide motif is a promising lead towards drugs to treat 
neuropathic and chronic pain. As such, further structure/activity studies are needed to fully understand the key determinants of its 
bioactivity and improve its drug-like properties. 
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